Molecule
Risedronate is a bisphosphonate indicated for treatment and prevention of postmenopausal osteoporosis, among other approved uses. It is available as tablets for oral use. MedsAcross supplies Risedronate for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
Risedronate sodium tablets are a bisphosphonate indicated for: Treatment and prevention of postmenopausal osteoporosis. Treatment to increase bone mass in men with osteoporosis. Treatment and prevention of glucocorticoid-induced osteoporosis. Treatment of Paget’s disease. Limitations of Use Optimal duration of use has not been determined. For patients at low-risk for fracture, consider drug discontinuation after 3 to 5 years of use.
Source: US FDA prescribing information
Risedronate has an affinity for hydroxyapatite crystals in bone and acts as an antiresorptive agent. At the cellular level, risedronate inhibits osteoclasts. The osteoclasts adhere normally to the bone surface, but show evidence of reduced active resorption (for example, lack of ruffled border). Histomorphometry in rats, dogs, and minipigs showed that risedronate treatment reduces bone turnover (activation frequency, that is, the rate at which bone remodeling sites are activated) and bone resorption at remodeling sites.
Source: US FDA prescribing information
Treatment of Postmenopausal Osteoporosis: 5 mg daily, 35 mg once-a-week, 75 mg two consecutive days each month, 150 mg once-a-month. Prevention of Postmenopausal Osteoporosis: 5 mg daily, 35 mg once-a-week. Men with Osteoporosis: 35 mg once-a-week. Glucocorticoid-Induced Osteoporosis: 5 mg daily. Paget’s Disease: 30 mg daily for 2 months. Instruct patients to: Swallow tablet whole with 6 to 8 ounces of plain water, at least 30 minutes before the first food, beverage, or medication of the day Avoid lying down for 30 minutes. Take supplemental calcium and vitamin D if dietary intake is inadequate
Source: US FDA prescribing information
Risedronate sodium is contraindicated in patients with the following conditions: Abnormalities of the esophagus which delay esophageal emptying such as stricture or achalasia Inability to stand or sit upright for at least 30 minutes Hypocalcemia Known hypersensitivity to risedronate sodium or any of its excipients. Angioedema, generalized rash, bullous skin reactions, Stevens-Johnson syndrome and toxic epidermal necrolysis have been reported Abnormalities of the esophagus which delay esophageal emptying such as stricture or achalasia. Inability to stand or sit upright for at least 30 minutes. Hypocalcemia. Known hypersensitivity to any component of this product
Source: US FDA prescribing information
Products Containing Same Active Ingredient: Patients receiving Atelvia should not be treated with risedronate sodium. Upper Gastrointestinal Adverse Reactions can occur. Instruct patients to follow dosing instructions. Discontinue use if new or worsening symptoms occur. Hypocalcemia may worsen and must be corrected prior to use. Osteonecrosis of the Jaw has been reported. Severe Bone, Joint, Muscle Pain may occur. Discontinue use if severe symptoms develop. Atypical Fractures Including Femoral Fractures have been reported. Patients with new thigh or groin pain should be evaluated to rule out a femoral fracture. Risk/benefit of continuing bisphosphonate therapy should be re-evaluated in these patients and interruption of bisphosphonate therapy should be considered
Source: US FDA prescribing information
The following clinically significant adverse drug reactions are described elsewhere in the labeling: Drug Products with the Same Active Ingredient Upper Gastrointestinal Adverse Reactions Mineral Metabolism Jaw Osteonecrosis Musculoskeletal Pain Atypical Fractures Including Femoral Fractures Renal Impairment Glucocorticoid-Induced Osteoporosis Laboratory Test Interactions Most common adverse reactions reported in greater than 10% of patients treated with risedronate and with a higher frequency than placebo are: back pain, arthralgia, abdominal pain, and dyspepsia. Hypersensitivity reactions (angioedema, generalized rash, bullous skin reactions, Stevens-Johnson syndrome, and toxic epidermal necrolysis), and eye inflammation (iritis, uveitis) have been reported rarely
Source: US FDA prescribing information
No specific drug-drug interaction studies were performed. Risedronate is not metabolized and does not induce or inhibit hepatic microsomal drug-metabolizing enzymes (for example, Cytochrome P450). Calcium, antacids, or oral medications containing divalent cations interfere with the absorption of risedronate
Source: US FDA prescribing information
Store at 20° to 25°C (68° to 77°F).
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
5 presentations of Risedronate, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Risedronate 35 mg tabletOralGeneric name | — | US FDA | Available on request |
| Risedronate 30 mg tabletOralGeneric name | — | US FDA | Available on request |
| Risedronate 5 mg tabletOralGeneric name | — | US FDA | Available on request |
| Risedronate 150 mg tabletOralGeneric name | — | US FDA | Available on request |
| Risedronate 75 mg tabletOralGeneric name | — | US FDA | Available on request |
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
| Register | Status | Source |
|---|---|---|
| US FDA | First approved 27 March 1998 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Conditions linked to Risedronate in public data. This is not a list of approved uses, see the clinical information.
Yes, on request. MedsAcross lists 5 presentations of Risedronate and sources them for licensed hospitals, importers and physicians against valid import documents.
Yes. The US FDA first approved Risedronate on 27 March 1998, according to Drugs@FDA.
No listed presentation of Risedronate is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Risedronate is classified under ATC code M05BA07 (Risedronate).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.